Intelligence · Clinical Development
Pipeline search results
Programs matching “Astra” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 467 pipeline programs matching "Astra" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
D9102C00001
AstraZeneca AB
Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions
1 trial -
D9106C00002
AstraZeneca AB
Non-small Cell Lung Cancer (NSCLC)
1 trial -
D9181C00002
AstraZeneca AB
Asthma
1 trial -
D933LC00001
AstraZeneca AB
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.
1 trial -
D9520C00001
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9571C00001
AstraZeneca AB
Relapsed/Refractory Classical Hodgkin Lymphoma
1 trial -
D967LC00001
AstraZeneca AB
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer
1 trial -
D9690C00006
AstraZeneca AB
Crohn’s Disease and an Ileostomy
1 trial -
D9720C00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D9720C00003
AstraZeneca AB
Metastatic Prostate Cancer
1 trial -
D9804C00001
AstraZeneca AB
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
1 trial -
DAROTAXEL
Disc Medicine
metastatic castration-resistant prostate cancer
1 trial -
DESTINY-Breast07
AstraZeneca AB
HER2-positive Metastatic Breast Cancer
1 trial -
DS-8201a
AstraZeneca AB
HER2 Expressing Tumors
1 trial -
DS-8201a
AstraZeneca AB
Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology
1 trial -
Datopotamab deruxtecan
AstraZeneca AB
Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy
1 trial -
Docetaxel
Merck KGaA, Darmstadt, Germany
Castration-Resistant Prostatic Cancer
1 trial -
EPI-7386, Xtandi - 40 mg soft capsules
Lacuna Pharma Pty Ltd
Metastatic castration-resistant prostate cancer
1 trial -
Enzalutamide 40mg
United Therapeutics Europe Ltd
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 trial -
Etrumadenant
Arcus Biosciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
Exicorilant
CORCEPT THERAPEUTICS INC
Metastatic Castration-Resistant Prostate Cancer
1 trial -
FirstHCMU-JBi-PARTOM
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
Fostamatinib
AstraZeneca
Rheumatoid Arthritis
1 trial -
Gefitinib
AstraZeneca
Head and Neck Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.